Photocure ASA represents strong values and a distinctive corporate philosophy. The company's core values include innovation, quality, and patient-centricity. Photocure is dedicated to developing and commercializing precise solutions for improved cancer diagnosis and treatment. By combining advanced technology and expertise, Photocure aims to make a positive impact on patients' lives and contribute to the healthcare system. The company's philosophy revolves around continuous growth, scientific excellence, and global leadership in photodynamic diagnosis and treatment. Photocure ASA constantly strives to deliver cutting-edge solutions and uphold its commitment to enhancing the quality of healthcare worldwide.

Photocure ASA is primarily present in various countries and regions worldwide. The company's presence extends to Europe, specifically Nordic countries like Norway, Sweden, Denmark, and Finland. Additionally, Photocure ASA also operates in the Americas with a strong focus on the United States, where its products are FDA-approved and widely used in the healthcare industry. With a global footprint, Photocure ASA continues to expand its market presence to cater to the growing demand for its innovative pharmaceutical and medical device solutions.

Photocure ASA, a leading pharmaceutical company, has achieved noteworthy milestones throughout its history. Notably, the company successfully launched Hexvix/Cysview, a breakthrough diagnostic tool for bladder cancer, in Europe and the United States. Photocure ASA further expanded its market presence by establishing strategic partnerships with reputable companies, such as Ipsen Pharma, GE Healthcare, and Asieris Pharmaceuticals. Additionally, the company obtained regulatory approvals for the use of Hexvix/Cysview in various countries. These significant achievements have solidified Photocure ASA's position as a key player in the field of bladder cancer diagnosis and treatment.

Photocure ASA, founded in 1997, is a Norwegian specialty pharmaceutical company focusing on photodynamic technology. With a strong commitment to improving patient outcomes, Photocure develops and commercializes innovative solutions for the diagnosis and treatment of bladder cancer. The company's flagship product is Hexvix/Cysview, a groundbreaking technology that enhances the detection and management of bladder cancer. Photocure ASA also collaborates with leading institutions and key opinion leaders to further research and develop its product portfolio. With a rich history spanning over two decades, Photocure ASA continues to revolutionize the field of bladder cancer diagnosis and treatment, aiming to positively impact patients worldwide.

The main competitors of Photocure ASA in the market include companies such as Johnson & Johnson, Bristol-Myers Squibb, and Novartis.

Photocure ASA is primarily active in the pharmaceutical industry, specifically within the field of photodynamic therapy. Photocure is renowned for its innovative solutions in the diagnosis and treatment of bladder cancer. Through its unique technology and products such as the photodynamic diagnostic system Hexvix/Cysview, Photocure has made significant contributions to improving patient outcomes in urology. With its focus on precision medicine and commitment to advancing bladder cancer care, Photocure ASA continues to make substantial strides in the medical industry.

The business model of Photocure ASA revolves around innovation and commercialization of pharmaceutical products within the field of photodynamic therapy. Photocure specializes in developing and marketing solutions for improved diagnosis and treatment of cancer. With a focus on photodynamic diagnosis (PDD) and photodynamic therapy (PDT), the company aims to enhance patient outcomes and reduce healthcare costs. Photocure's flagship product, Hexvix/Cysview, is used for the detection and management of bladder cancer. By leveraging its expertise in photodynamic technology, Photocure continues to explore and expand its product portfolio to address unmet medical needs in various cancer types.

De Photocure A K/W is -410,81.

De Photocure A KUV is 2,67.

De AlleAktien Kwaliteitsscore voor Photocure A is 3/10.

De verwachte Photocure A omzet is 505,64 mln. NOK.

De verwachte Photocure A winst is -3,29 mln. NOK.

Photocure ASA is a Norwegian company specializing in the development, production, and marketing of imaging diagnostics and pharmaceutical products for the diagnosis and treatment of cancer. The company focuses on providing solutions that support doctors in the diagnosis and treatment of cancer. Photocure operates in two main business areas. The first area focuses on the marketing of cystoscopy products for the diagnosis of bladder cancer under the brand name Cysview. Cysview is a fluorescence-based technology that allows doctors to quickly and accurately identify cancer cells in the bladder, especially during endoscopic procedures such as cystoscopy. The company has a network of distribution partners worldwide and has made significant progress in introducing its product in key markets such as the USA and Europe. The second business area focuses on the research and development of cancer drugs. Photocure has several pharmaceutical product candidates in various stages of development, including a treatment for prostate cancer and a drug for the treatment of skin cancer. The company's portfolio is evidence of its commitment to promoting innovation in the fight against cancer. Photocure is also known for its strong focus on research and development, with an advanced research and development department dedicated to developing new technologies and therapies. Investments in research and development are an important part of Photocure's business model, allowing the company to expand its market and explore new opportunities. Over the years, Photocure has gained a strong position in the cancer diagnostics and treatment market and aims to continue growing through the introduction of new products and technologies. The company has a track record of developing and marketing innovative products and solutions to combat cancer and improve healthcare. In summary, Photocure ASA offers a broad range of products and solutions for the diagnosis and treatment of cancer. The company is known for its advanced technologies and strong focus on research and development. Photocure is a company with a clear vision for the future and a commitment to innovation and excellence in all aspects of its business.

Photocure A keert een dividend van 0 NOK uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Photocure A of het bedrijf keert geen dividend uit.

De ISIN van Photocure A is NO0010000045.

Het WKN van Photocure A is 931150.

De ticker van Photocure A is PHO.OL.

Binnen de laatste 12 maanden betaalde Photocure A een dividend van 2,00 NOK . Dit komt overeen met een dividendrendement van ongeveer 4,02 %. Voor de komende 12 maanden zal Photocure A naar verwachting een dividend van 0 NOK betalen.

De dividendrendement van Photocure A is momenteel 4,02 %.

Photocure A betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Photocure A betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 NOK verwacht. Dit komt overeen met een dividendrendement van 0 %.

Photocure A wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Photocure A van 11-6-2013 ter hoogte van 2 NOK te ontvangen, moest je het aandeel voor de ex-datum op 23-5-2013 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 11-6-2013.

In het jaar 2023 heeft Photocure A 0 NOK aan dividenden uitgekeerd.

De dividenden van Photocure A worden in NOK uitgekeerd.